Alongside traditional water extraction, the NordRelease extraction process is now the only extraction process to have been approved by the E.U. for functional mushroom extracts, according to the company. This official non-novel status for KÄÄPÄ Biotech’s NordRelease mushroom extract powders represents the largest innovation in this space in decades and firmly demonstrates that KÄÄPÄ Biotech is dedicated to leading the way in this industry.

“We’re beyond thrilled that EFSA has verified what we knew all along. That our NordRelease extraction process provides the best quality to our customers. This extraction process is undeniably the best way to extract the bioactive compounds from mushrooms versus traditional water extraction,” said Eric Puro, CEO and co-founder of KÄÄPÄ Biotech. “We have an amazing team doing incredible work in this space. The functional mushroom market continues to grow at an incredible rate and we’re proud to not only be a part of it, but to be taking it in exciting new directions. Over 180 customers have put their trust in us to deliver on our promises of bringing them the best quality product, with today’s announcement signaling that we’re doing just that.”

NordRelease, based upon Ultrasonic Assisted Extraction (UAE), was developed and created by the science team at KÄÄPÄ Biotech. After years of pioneering and evolving UAE, KÄÄPÄ Biotech took the initiative to trademark its proprietary extraction technology in an effort to highlight the gulf in quality often seen in the market.

As recently as April 15, 2025, KÄÄPÄ Biotech announced that it had closed a €900,000 strategic investment from PeakBridge, a pioneering global fund manager in agri-food and a member of the Edmond de Rothschild Private Equity partnership. This strategic investment will help drive a new phase of growth as KÄÄPÄ Biotech continues to scale its business to match the increase in customer demands.

For more information, visit https://kaapabiotech.com.